Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic ...

Second, the medicine everyone thought would take over the industry, Novo Nordisk's CagriSema, did not perform as well as expected in a phase 3 study. CagriSema could still be a commercial success ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Mexico's President Claudia Sheinbaum said on Sunday that reason should prevail a day after her government and the U.S. announced tariffs against one another, raising her fist in the air as she ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...

(Bloomberg) -- Novo Nordisk A/S investors got a much-needed ... coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed Novo ...